Pauling David 4

What Happened
David Pauling, Chief Administrative Officer & General Counsel of Sutro Biopharma (STRO), had 675 restricted stock units (RSUs) convert/settle into common shares on March 4, 2026. The company withheld 277 of those shares to satisfy income tax withholding at $21.31 per share (total value withheld ≈ $5,903). After withholding, Pauling received 398 net shares. This was a vesting/settlement event (not an open-market purchase or sale by the insider).

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely filing).
• Conversion/settlement: 675 RSUs -> 675 shares (code M) at $0.00 reported per-share exercise price.
• Tax withholding: 277 shares withheld (code F) at $21.31/share = $5,903 withheld; withholding is not an open-market sale by the insider.
• Net shares received from this vesting: 398 shares.
• Shares beneficially owned after the transaction: not specified in the provided excerpt.
• Relevant footnotes: F1 = shares withheld to satisfy income tax withholding (not a sale); F2 = each RSU converts to one share; F3 = RSUs vest 1/4 annually with first tranche on 3/4/2023, subject to continued service.

Context

• Code M indicates conversion/exercise of a derivative (here, RSUs) into common stock. Code F shows shares withheld to cover tax obligations — a common administrative step in net settlements.
• This is a routine vesting/net-settlement event and does not necessarily signal a buy or sell decision by the insider.